Processa Pharmaceuticals IncNASDAQ PCSA Stock Report

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Hanover Maryland, Maryland and currently employs 15 full-time employees. The company went IPO on 2013-10-07. The company is focused on development of drug products that are intended to provide treatment for patients who have unmet medical need condition that effects survival or the patient’s life and no treatment options. The company has five drugs: four in various stages of clinical development (PCS499, PCS12852, PCS3117 and PCS6422) and one in nonclinical development (PCS11T). PCS499 is an oral tablet that is a deuterated analog of one of the major metabolites of pentoxifylline (PTX ). PCS12852 is a highly specific and potent 5-hydroxytryptamine 4 (5-HT4) receptor agonist. is a novel, investigational, oral small molecule nucleoside compound. PCS3117 is an analog of the endogenous nucleoside, cytidine, and an analog of the cancer drug gemcitabine. PCS6422 is an oral, potent, selective and irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD). PCS11T is being developed for the treatment of the solid tumor.